For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2020

27 May - 1 Jun 2020

Chicago, United States of America

ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer

ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer

ASCO 2020: Blood test predicts response to prostate cancer treatment

ASCO 2020: Blood test predicts response to prostate cancer treatment

ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumours

ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with ...

ASCO 2020: Trastuzumab combined with trimodality treatment does not improve outcomes for patients

ASCO 2020: Trastuzumab combined with trimodality treatment does not improve outcomes for patients

ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment

ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment

ASCO 2020: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response

ASCO 2020: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutat...

ASCO 2020: Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS

ASCO 2020: Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS

ASC0 2020: Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy

ASC0 2020: Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET ge...

ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma

ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal...

ASCO 2020: Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML

ASCO 2020: Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AM...

ASCO 2020: Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations

ASCO 2020: Pembrolizumab doubles time to disease progression in patients with advanced colorectal ca...

ASCO 2020: Post-surgery osimertinib delays disease recurrence in patients with localised non-small cell lung cancer

ASCO 2020: Post-surgery osimertinib delays disease recurrence in patients with localised non-small c...

ASCO 2020: Multinational consortium reports COVID-19 impact on cancer patients

ASCO 2020: Multinational consortium reports COVID-19 impact on cancer patients

ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemotherapy

ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemoth...

ASCO 2020: Surgery and radiation do not extend survival in newly diagnosed metastatic breast cancer

ASCO 2020: Surgery and radiation do not extend survival in newly diagnosed metastatic breast cancer

ASCO 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial cancer

ASCO 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced u...

ASCO 2020: Chemo within 3 months of COVID-19 diagnosis associated with an increased risk of death in patients with thoracic cancer

ASCO 2020: Chemo within 3 months of COVID-19 diagnosis associated with an increased risk of death in...

ASCO 2020: Large scale precision medicine approach successfully applied to paediatric cancers with poor prognosis

ASCO 2020: Large scale precision medicine approach successfully applied to paediatric cancers with p...

ASCO 2020: Special report provides guidance to oncology practices on resuming cancer care during COVID-19 pandemic

ASCO 2020: Special report provides guidance to oncology practices on resuming cancer care during COV...

ASCO 2020: Early data show cancer progression associated with increased risk of death in patients with COVID-19

ASCO 2020: Early data show cancer progression associated with increased risk of death in patients wi...

ASCO 2020: Pembrolizumab plus chemotherapy demonstrated improvement in PFS for patients with metastatic triple-negative breast cancer

ASCO 2020: Pembrolizumab plus chemotherapy demonstrated improvement in PFS for patients with metasta...

ASCO 2020: Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

ASCO 2020: Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy in metastatic first-line non-small cell lung cancer patients

ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over ...

ASCO 2020: Apalutamide significantly improved overall survival in patients with non-metastatic castration-resistant prostate cancer

ASCO 2020: Apalutamide significantly improved overall survival in patients with non-metastatic castr...

ASCO 2020: Video conference intervention significantly reduces anxiety and distress among remote caregivers of people with cancer

ASCO 2020: Video conference intervention significantly reduces anxiety and distress among remote car...

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patie...

More from ecancer